One in every 500 newborns worldwide are affected by nonsyndromic hearing loss (NSHL). Whole-exome sequencing may help in identifying the genetic cause of NSHL.

Researchers from Sun Yat-sen University Cancer Center (SYSUCC) presented data from a study that aimed to assess the role of trophoblast cell-surface antigen-2 (TROP-2) in penile squamous cell carcinoma (PSCC).

Astrazeneca plc’s blockbuster Enhertu continued to garner attention as new data released at the American Society of Clinical Oncology (ASCO) annual meeting show the antibody-drug conjugate demonstrated strong progression-free survival in metastatic breast cancer patients. Puma Biotechnology Inc. had advances of its own at ASCO with new biomarker findings from a phase II study of alisertib, an aurora protein kinase 2 inhibitor, in endocrine-resistant metastatic breast cancer.

While Servier Pharmaceuticals LLC awaits this summer’s PDUFA date for the IDH-mutant glioma drug vorasidenib, acquired in the buyout of oncology assets from Agios Pharmaceuticals Inc., the latter unveiled positive data from a global phase III study with oral mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia.

Researchers from Federation University Australia and affiliated organizations have reported data from a study that aimed to assess the therapeutic efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in a large animal model of pulmonary fibrosis.

Researchers from Purespring Therapeutics Ltd. and affiliated organizations have presented preclinical data for the adeno-associated vector (AAV) gene therapy PS-001 for the treatment of glomerular disease.

Researchers from Australis Pharmaceuticals Pty Ltd. have presented preclinical data for the microtubule-destabilizing agent AUS-001, which is being evaluated in models of glioblastoma (GBM).